Picture of AnaptysBio logo

ANABV — AnaptysBio News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapHigh Flyer

AnaptysBio Inc expected to post a loss of $1.57 a share - Earnings Preview

* AnaptysBio Inc  ANAB.OQ   ANAB.O  is expected to show a
rise in
quarterly revenue when it reports  results on May 9 (estimated)
for the period ending March 31 2024
    * The San Diego California-based  company is expected to
report a
188.7% increase in revenue to $3.967 million from $1.37 million
a year ago, according to the mean estimate from 10 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for AnaptysBio Inc is for a
loss
of $1.57 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 1.1%
in the last three months. ​
    * Wall Street's median 12-month price target for AnaptysBio
Inc is
$47.00​, above​ its last closing price of $25.77. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -1.62       -1.60      -1.59     Beat    0.7
 Sep. 30 2023  -1.80       -1.79      -1.41     Beat    21.4
 Jun. 30 2023  -1.83       -1.70      -1.50     Beat    11.6​
 Mar. 31 2023  -1.08       -1.05      -1.58     Missed  -50.8
 ​​Dec.        -0.96       -0.96      -0.93     Beat    2.8
 31 2022                                                
 Sep. 30 2022  -0.65       -0.72      -1.18     Missed  -63.1​
 Jun. 30 2022  -0.89       -1.02      -1.15     Missed  -12.6
 Mar. 31 2022  -1.02       -0.99      -1.31     Missed  -31.7
 This summary was machine generated May 7 at 12:06 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on AnaptysBio

See all news